Abstract

This sub-analysis aimed to determine the safety and effectiveness of biphasic insulin aspart30 (BIAsp30) therapy in people with type 2 diabetes (T2D) from Morocco as a part of the global, 24-week, non-interventional A₁chieve study. A total of 770 Moroccan T2D patients, both insulin-naïve patients and prior insulin users, who started BIAsp 30 therapy at their physicians’ discretion, were included. Baseline glycaemic control was poor in the Moroccan cohort with a mean (±SD) glycated haemoglobin A_1c(HbA_1c) of 9.8 ± 1.8%. After 24 weeks, mean HbA_1c significantly reduced by -2.2 ± 1.7% in the Moroccan cohort (-2.5 ± 1.8% in insulin-naïve patients and -1.9 ± 1.5% in prior insulin users, all p<0.001). In the entire cohort, there was no significant difference from baseline to Week 24 in the percentage of patients with at least one event of overall or minor hypoglycaemia, while there was a significant reduction in the percentage of patients reporting at least one event of major or nocturnal hypoglycaemia (p<0.0001). Mean body weight increased (1.4 ± 4.3 kg), while the lipid profile and systolic blood pressure improved over 24 weeks. Overall, BIAsp 30 therapy was well-tolerated and improved glycaemic control in Moroccan T2D patients.

Key words: Type 2 diabetes, BIAsp 30, Morocco, non-interventional study, glycaemic control.